DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
| Revenue (TTM) | $14.17B |
| Gross Profit (TTM) | $4.57B |
| EBITDA | $2.85B |
| Operating Margin | 15.50% |
| Return on Equity | 96.80% |
| Return on Assets | 7.59% |
| Revenue/Share (TTM) | $213.39 |
| Book Value | $-9.32 |
| Price-to-Book | 21.63 |
| Price-to-Sales (TTM) | 0.85 |
| EV/Revenue | 1.77 |
| EV/EBITDA | 8.93 |
| Quarterly Earnings Growth (YoY) | 66.70% |
| Quarterly Revenue Growth (YoY) | 4.60% |
| Shares Outstanding | $62.90M |
| Float | $33.44M |
| % Insiders | 46.97% |
| % Institutions | 49.55% |
Volatility is currently expanding
DaVita HealthCare (DVA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
DENVER, Nov. 3, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its Chief Financial Officer, Joel Ackerman, and its Group Vice President of Investor Relations, Nic Eliason, will participate in fireside chats at the following upcoming investor conferences: UBS Global Healthcare Conference 2026 Date: Monday, November 9, 2026 Fireside Chat Presentation: 1:15 pm EST To view the live webcast, visit the UBS conference page and create a free registration. Wolfe Research Healthcare Conference 2026 Date: Tuesday, November 10, 2026 Fireside Chat Presentation: 8:40 am EST To view the live webcast, visit the Wolfe conference page and create a free registration.
DVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
DaVita NYSE: DVA reported third-quarter adjusted operating income of $561 million, adjusted earnings per share of $3.82 and free cash flow of $276 million, while narrowing its full-year 2026 outlook. The kidney-care provider said its Integrated Kidney Care business outperformed expectations, though higher technology spending continued to weigh on U.S. dialysis results.
DENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026: Consolidated revenues were $3.578 billion.
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.
Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chronic disease and don't know it. The risks are often interconnected: High blood pressure and diabetes can increase the risk of kidney disease, while chronic kidney disease (CKD) often progresses without symptoms.
DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DVA and any ticker you trade — then tracks every position and per-strategy win rate.
